N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
N/A N=38 Mechanisms of Obesity and Its Metabolic Complications in Youth
Obesity, Childhood
Primary: Rate of Appearance of Acetate — 7.40; 7.69; 9.29; 14.7 umol/kg/min
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
N/A N=98 Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Phase 4 N=20 Metabolic Abnormalities in HIV-infected Persons
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=61 Sex Steroids, Sleep, and Metabolic Dysfunction in Women
Polycystic Ovary Syndrome (PCOS) · Obstructive Sleep Apnea · Obesity
Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85
N/A N=8,493 Monitoring and Management for Metabolic Side Effects of Antipsychotics
Mental Health · Psychotic Disorders
Primary: Change in Site-level Rates of Weight Monitoring at Baseline (Within 30 Days of a New Antipsychotic Prescription) — 1811; 1410; 1598; 1109 Participants
N/A N=61 Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
Hypertension
Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
N/A N=89 Long Duration Activity and Metabolic Control After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: NR4A3 mRNA Expression Pre and Post-Stimulation — 3.235; 2.711; 6.286; 5.772 arbitrary units — p=<0.001
Phase 4 N=54 Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Gestational Diabetes · Diabetes, Gestational · Pregnancy in Diabetes
Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
N/A N=96 Glucose and Lipid Metabolism on Antipsychotic Medication
Schizophrenia · Schizoaffective Disorder · Type 2 Diabetes Mellitus
Primary: DEXA Total Fat — 32.24; 27.66; 28.83; 31.60 kilograms of body fat — p=0.002
Phase 4 N=144 Metabolic Effects of Antipsychotics in Children
Aggression · Attention Deficit-Hyperactivity · Oppositional Defiant Disorder
Primary: Change in DEXA % Body Fat — 1.81; 4.12; 1.66 percent body fat — p=<0.0001
N/A N=129 Metabolic Impact of Intermittent CPAP
Obstructive Sleep Apnea
Primary: Concentration of Plasma Free Fatty Acids (FFA, mmol/L) — 0.47; 0.51 mmol/L
N/A N=43 Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery
Obesity · Diabetes · Heart Failure
Primary: Change in Weight — -21.5; -16.4 kg — p=<.0001
N/A N=20 Hepatic Mitochondrial Function in Youth
Hepatic Steatosis · Bariatric Surgery Candidate · Adolescent Obesity
Primary: Change in Percentage of Liver Fat Per MRI — -13.93 percentage of liver fat
N/A N=30 Effect of Endoplasmic Reticulum Stress on Metabolic Function
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Phase 4 N=25 Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
Metabolic Complications
Primary: Weight Gain — 2.54; 5.88 kilogram
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
N/A N=33 Time Restricted Eating for Metabolic and Psychological Optimization
Mild Cognitive Impairment · Obesity
Primary: Change in Memory Composite Rank — 6.22 rank — p=<0.001
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L